Biora Therapeutics (BIOR) said Monday it filed a voluntary petition for Chapter 11 in the district of Delaware to strengthen its balance sheet and support the next stage of product development.
The biotech company also said it reached an agreement with some of its pre-petition creditors to secure financing as part of the Chapter 11 sale process.
The drug developer said it has secured a debtor-in-possession financing facility of up to $10.25 million, subject to court approval, to continue normal operations and meet obligations to vendors, suppliers, employees, and other stakeholders. Biora added that it plans to file a motion to approve a competitive marketing and sale process under the Bankruptcy Code to minimize disruptions.
As part of the transaction, the company said its lenders will act as a stalking horse bidder for its assets.
Biora added it expects to continue paying employee wages and vendor obligations during the Chapter 11 proceedings.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.